Pediatric Ophthalmology, An Issue of Pediatric Clinics -  Mary Lou McGregor

Pediatric Ophthalmology, An Issue of Pediatric Clinics (eBook)

eBook Download: PDF | EPUB
2014 | 1. Auflage
161 Seiten
Elsevier Health Sciences (Verlag)
978-0-323-29946-6 (ISBN)
71,39 € inkl. MwSt
Systemvoraussetzungen
63,74 € inkl. MwSt
Systemvoraussetzungen
  • Download sofort lieferbar
  • Zahlungsarten anzeigen
Pediatric Ophthalmology, An Issue of Pediatric Clinics,
As the authors describe in this volume dedicated to vision in children, great strides have been made in recent years in preventing and identifying any loss of visual acuity, and, when identified, correcting it. The articles are written for the practicing pediatrician and describe conditions that are detected in pediatric practice and/or about which parents and patients may be knowledgeable and have questions. Articles in this issue are devoted to: Pediatric Refractive Surgery; The Lacrimal System; Periocular Hemangiomas and Lymphangiomas; Genetics and Ocular Disorders: A Focused Review; Retinopathy of Prematurity; Review of Pediatric Idiopathic Intracranial Hypertension; Allergic Eye Disease; and Convergence Insufficiency and Vision Therapy, to name a few.

Front Cover 1
Pediatric Ophthalmology 2
copyright 
3 
Contributors 6
Contents 8
Pediatric Clinics Of 

11 
Foreword 12
References 13
Preface 14
A Child’s Vision 16
Key points 16
Introduction 16
What is normal visual behavior? 16
How to assess an infant’s vision 17
The red reflex test 18
Nystagmus 20
Delayed visual maturation 20
Cortical vision impairment 20
Vision screening 21
Instruments for vision screening 21
Summary 23
References 23
Amblyopia 26
Key points 26
How well do glasses alone treat amblyopia? 27
Do we really know that patching works? 27
How many daily hours of prescribed patching are necessary? 27
What happens when patching stops? 32
Does patching work in older children? 32
Does atropine work as well as patching? 32
How often does atropine need to be used? 32
l-Dopa in the treatment of amblyopia 32
Screening for amblyopia 33
Classification 35
Diagnosis 35
Treatment 36
Complications 37
Summary 37
References 37
Pediatric Refractive Surgery 40
Key points 40
Introduction 40
Historical perspective 40
Refractive surgery procedures today in adults 41
Low-to-moderate Myopia and Low Hyperopia 41
High Myopia 41
Moderate-to-high Hyperopia 42
Challenges of pediatric refractive surgery 42
Indications for Treatment 43
Patient Cooperation 45
Desired Postoperative Correction 45
More Challenging Refractive Errors 45
Future role of refractive technology in children 46
Refractive Surgery in the Adolescent Population 46
Identifying and Treating Highly Anisometropic Eyes Earlier 46
Summary 46
References 46
The Lacrimal System 50
Key points 50
Definition and anatomy 50
Physiology and function 51
Embryology and development 52
Congenital disorders and treatment 52
Congenital Nasolacrimal Duct Obstruction 52
Clinical features 52
Management 53
Nonsurgical 53
Surgical 53
Congenital Dacryocystocele (Dacryocele) 55
Clinical features 55
Management 55
Congenital Lacrimal Fistula 55
Clinical features 55
Management 55
Congenital Alacrima 56
Congenital Paradoxic Gustolacrimal Reflex (Crocodile Tears) 56
Atresia of the Punctum or Canaliculus 56
Lacrimal Gland Choristoma 56
Acquired disorders and treatment 57
Dacryocystitis 57
Dacryoadenitis 57
Canaliculitis 57
Punctal or Canalicular Stenosis 57
Association with Facial Abnormalities 57
Clinical assessment 57
History and External Examination 57
Testing 58
Pediatricians’ and ophthalmologists’ tests 58
Dye disappearance test 58
Lacrimal sac compression 58
Ophthalmologists’ tests 58
Tear breakup time (TBUT) 58
Schirmer I and Schirmer II test 58
Jones I and Jones II test 58
Irrigation 58
Dacryocystogram 59
Nasal endoscopy 59
Computed tomography and magnetic resonance imaging 59
References 59
Periocular Hemangiomas and Lymphangiomas 62
Key points 62
Introduction 62
Hemangioma 63
Extent of Problem 63
Cause, Contributory Factors, Risk Factors 64
Sequelae of the problem 64
Clinical Assessment 65
Kasabach-Merritt Syndrome 66
PHACE Syndrome 66
Management 66
Pretreatment considerations 67
Induction of systemic propranolol 68
Monitoring 68
Lymphangioma (lymphatic and venous-lymphatic malformations) 69
Extent of Problem 69
Cause, Contributory Factors, Risk Factors 70
Sequelae of the Problem 70
Clinical Assessment 70
Management 70
References 72
Genetics and Ocular Disorders 76
Key points 76
Introduction 76
Selected clinically important ocular phenotype/genotype correlations 77
Lids 77
Lymphedema-distichiasis syndrome 77
Cornea 77
Corneal lesion and trisomy 8 mosaicism 77
Iris 77
Iris anomalies and ACTA2 77
Lens 78
Vitreous 78
Vitreous anomaly and stickler syndrome 78
Retina 78
Leber congenital amaurosis 78
Photophobia 79
Nyctalopia 79
Optic Nerve 79
Glaucoma 80
Development of groupings of diseases and syndromes based on cellular events or pathways 80
Ciliopathies 80
RASopathies 82
Overview of genetic testing and principles 82
Karyotype 82
Microarray-Based Technologies 82
Sequencing 83
Deletion/Duplication Studies 84
New therapies for genetic eye disease 84
Summary 85
References 85
Retinopathy of Prematurity 88
Key points 88
Introduction 88
Extent of the problem 88
Cause/contributory or risk factors 89
Sequelae 89
Clinical assessment 90
Management 92
Summary 94
References 94
A Review of Pediatric Idiopathic Intracranial Hypertension 100
Key points 100
Introduction 100
Nomenclature 101
Demographics 101
Associated conditions 101
Clinical presentation 101
Evaluation 102
Diagnostic criteria 105
Workup 106
Treatment 107
Emergent treatment 108
Pharmacologic treatment 108
Surgical treatment 108
Summary 109
References 109
The Pediatric Red Eye 112
Key points 112
Etiology and contributory or risk factors 112
Tools to evaluate the red eye 112
History 113
The red eye causes and treatments 113
Viral Conjunctivitis 113
Pharyngoconjunctival fever 115
Herpetic eye disease 115
Molluscum contagiosum 117
Bacterial Conjunctivitis 117
Treatment 117
Neonatal Conjunctivitis 118
Cellulitis 119
Treatment of cellulitis 119
Inflammatory Conjunctivitis 120
Uveits 120
Chalazion 120
Blepharitis 121
Structural 121
Trauma and Foreign Body 124
Corneal abrasion or foreign body 124
Contact lens wear 125
Trauma 125
Toxic and Chemical Exposure 125
References 126
Allergic Eye Disease 128
Key points 128
Introduction 128
Classification 131
Seasonal Allergic Conjunctivitis 131
Epidemiology and risk factors 131
Pathophysiology 131
Clinical presentation 131
Perennial Allergic Conjunctivitis 131
Epidemiology and risk factors 131
Pathophysiology 131
Clinical presentation 131
Vernal Keratoconjunctivitis 131
Epidemiology and risk factors 131
Pathophysiology 132
Clinical features 132
Atopic Keratoconjunctivitis 133
Epidemiology and risk factors 133
Pathophysiology 133
Clinical features 133
Contact Blepharoconjunctivitis 134
Epidemiology and risk factors 134
Pathophysiology 134
Clinical features 134
Giant Papillary Conjunctivitis 135
Epidemiology and risk factors 135
Pathophysiology 135
Clinical features 135
Clinical assessment 135
History 135
Examination 135
Differential Diagnosis 136
Management 136
Sequelae of the problem 137
Acknowledgments 140
References 140
Convergence Insufficiency and Vision Therapy 142
Key points 142
What are the symptoms of CI? 143
How to test convergence and diagnose CI 143
Secondary causes of convergence insufficiency 144
Who needs treatment for CI? 145
What is the treatment for CI? 146
Controversies over vision therapy between the optometric and ophthalmic communities 147
Learning disabilities 147
Summary 149
References 150
Index 152

Amblyopia


Diana DeSantis, MDddesantis@cepcolorado.com,     Children's Eye Physicians, 4875 Ward Road, Wheat Ridge, CO 80033, USA

Amblyopia refers to unilateral or bilateral reduction in best corrected visual acuity, not directly attributed to structural abnormality of the eye or posterior visual pathways. Early detection of amblyopia is crucial to obtaining the best response to treatment. Amblyopia responds best to treatment in the first few years of life. In the past several years a series of studies undertaken by the Pediatric Eye Disease Investigator Group (PEDIG) have been designed to evaluate traditional methods for treating amblyopia and provide evidence on which to base treatment decisions. This article summarizes and discusses the findings of the PEDIG studies to date.

Keywords

Amblyopia

Atropine

Levodopa

Patching

Key points


• Amblyopia is the most common cause of vision loss in children.

• Early detection and treatment of amblyopia are critical to restoring vision in amblyopic eyes.

• Regular vision screening and appropriate referral to a pediatric ophthalmologist are important steps in the detection of children at risk for amblyopia.

• The Pediatric Eye Disease Investigator Group (PEDIG) has published several studies in recent years providing evidence on which to base treatment decisions. Newer treatments including atropine drops and oral levodopa have been evaluated.

With an estimated prevalence of 2% to 4% in North America, amblyopia accounts for more cases of unilateral reduced vision in children than all other causes combined.1 By definition, amblyopia refers to unilateral or, less commonly, bilateral reduction in best corrected visual acuity, not directly attributed to a structural abnormality of the eye or posterior visual pathways.1 Its primary causes are strabismus, anisometropia (significant difference in refractive error between the 2 eyes) or bilateral high refractive errors, and stimulus deprivation. Early detection of amblyopia is crucial in obtaining the best response to treatment. If amblyopia goes unrecognized or untreated past the early years of life, it often cannot be successfully treated and vision cannot be fully restored in the amblyopic eye. Although there are exceptions to the rule, most ophthalmologists regard the age of visual maturity to be approximately 8 to 9 years of age. Beyond visual maturity, most cases of amblyopia respond poorly to any form of treatment. It is also generally accepted that amblyopia responds best to treatment in the first few years of life.

The earliest clinical description of human amblyopia is generally credited to Le Cat in 1713. Although amblyopia as a disease has been relatively well understood for many years and the treatment modalities have remained fairly standard, in the past several years much has been published regarding this disease, owing mostly to a series of Amblyopia Treatment Studies (ATS) undertaken by the Pediatric Eye Disease Investigator Group (PEDIG). These studies were designed to evaluate the traditional methods for treating amblyopia and provide evidence on which to base treatment decisions. Before the PEDIG studies, most published studies on amblyopia treatment were large retrospective reviews.2

Formed in 1997, and funded by the National Eye Institute, PEDIG is a collaborative network facilitating multicenter clinical research in strabismus, amblyopia, and other eye disorders that affect children. There are more than 100 participating sites with more than 200 pediatric ophthalmologists and optometrists in the United States, Canada, and the United Kingdom. PEDIG has completed more than 15 ATS to date, many with multiple phases. The published findings of the PEDIG ATS to date are summarized in Table 1.

Table 1

Pediatric Eye Disease Investigator Group studies with published results

Randomized trial comparing occlusion vs pharmacologic for moderate amblyopia (ATS 1) 419 (3 to <7 y) 6 mo VA improved in both groups: 3.16 lines in occlusion group; 2.84 lines in atropine group
Mean difference = 0.34 lines (95% CI, 0.05–0.6)
VA ≥20/30 and/or improved by ≥3 lines in 79% of occlusion group and 74% of atropine group
Randomized trial comparing occlusion vs pharmacologic therapy for moderate amblyopia (ATS 1) 419 (3 to <7 y) 2 y VA improved in both groups: 3.7 lines in occlusion group; 3.6 lines in atropine group
Mean difference = 0.01 lines (95% CI, −0.02 to 0.04)
Atropine or patching for an initial 6-mo period produced a similar improvement in amblyopia 2 y after treatment
Randomized trial comparing part-time vs full-time patching for severe amblyopia (ATS 2A) 175 (3 to <7 y) 4 mo VA improved in both groups: 4.8 lines in the 6-h patching group; 4.7 lines in the full-time patching (all hours or all but 1 h per day) group
Mean difference = 0.02 lines (95% CI, −0.04 to 0.07)
Randomized trial comparing part-time vs minimal-time patching for moderate amblyopia (ATS 2B) 189 (3 to <7 y) 4 mo VA improvement in both groups was 2.40 lines
Mean difference = −0.007 lines (95% CI, −0.050 to 0.036)
VA ≥20/32 and/or ≥3 lines in 62% of patients in both groups
VA improvement similar for 2 h of daily patching and 6 h of daily patching
Evaluation of treatment of amblyopia (ATS 3) 507 (7–17 y) 6 mo For moderate amblyopia in children 7 to <13 y old, 36% achieved 20/25 or better with optical correction/occlusion/atropine use compared with 14% with optical correction alone (P<.001)
For severe amblyopia in children 7 to <13 y old, 23% achieved 20/40 or better with optical correction/patching compared with 5% with optical correction alone (P<.004)
For moderate amblyopia in teenagers 13–17 y old, 14% achieved 20/25 or better with optical correction/occlusion compared with 11% with optical correction alone (P = .52)
For severe amblyopia in teenagers 13–17 y old, 14% achieved 20/25 or better with optical correction/occlusion compared with 0% with optical correction alone (P = .13)
Randomized trial comparing daily atropine vs weekend atropine for moderate amblyopia (ATS 4) 168 (3 to <7 y) 4 mo VA improvement in both groups was 2.3 lines
Mean difference = 0.00 (95% CI, −0.04 to 0.04)
47% of daily group and 53% of the weekend group had either VA ≥20/25 or greater than or equal to that of the nonamblyopic eye
Prospective noncomparative trial to evaluate 2 h of daily patching for amblyopia (ATS 5, eyeglasses-only phase) 84 (3 to <7 y) Up to 30 wk Amblyopia improved with optical correction by ≥2 lines in 77%
Amblyopia resolved with optical correction in 27% (95% CI, 18%–38%)
Randomized trial to evaluate 2 h daily patching for amblyopia (ATS 5, randomization phase) 180 (3 to <7 y) 5 wk After a period of treatment with eyeglasses until vision stopped improving, patients treated with 2 h of daily patching combined with 1 h of near visual tasks had an improvement in VA of 1.1 lines compared with 0.5 lines in the control group
Mean difference (adjusted) = 0.07 lines (95% CI, 0.02–0.12; P = .006)
Randomized trial to compare near vs distance activities while occluded (ATS 6) 425 (3 to <7 y) 17 wk At 8 wk, improvement in amblyopic eye VA averaged 2.6 lines in the distance activities group and 2.5 lines in the near activities group (95% CI for difference, −0.3 to 0.3 line)
Groups appeared statistically similar at the 2-wk, 5-wk, and 17-wk visits
At 17 wk, children with severe amblyopia improved a mean of 3.7 lines with 2 h patching
Treatments of bilateral refractive amblyopia (ATS 7) 113 (3 to <10 y) 1 y Binocular VA improved on average 3.9 lines (95% CI, 3.5–4.2)
At 1 y, 74% had binocular VA of 20/25 or better
Randomized trial comparing atropine vs atropine plus a plano lens for the fellow eye in children 3–6 y (ATS 8) 180 (3 to <7 y) 18 wk Ambloypic eye VA was 20/25 or better in 29% of the atropine-only group and in 40% of the atropine plus plano lens group (P = .03)
More patients in the atropine plus plano lens group had reduced fellow eye acuity at 18 wk; however, there were no cases of persistent reverse...

Erscheint lt. Verlag 9.8.2014
Sprache englisch
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Augenheilkunde
Medizin / Pharmazie Medizinische Fachgebiete Pädiatrie
ISBN-10 0-323-29946-6 / 0323299466
ISBN-13 978-0-323-29946-6 / 9780323299466
Haben Sie eine Frage zum Produkt?
PDFPDF (Adobe DRM)
Größe: 7,8 MB

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: PDF (Portable Document Format)
Mit einem festen Seiten­layout eignet sich die PDF besonders für Fach­bücher mit Spalten, Tabellen und Abbild­ungen. Eine PDF kann auf fast allen Geräten ange­zeigt werden, ist aber für kleine Displays (Smart­phone, eReader) nur einge­schränkt geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

EPUBEPUB (Adobe DRM)

Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM

Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belle­tristik und Sach­büchern. Der Fließ­text wird dynamisch an die Display- und Schrift­größe ange­passt. Auch für mobile Lese­geräte ist EPUB daher gut geeignet.

Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine Adobe-ID und die Software Adobe Digital Editions (kostenlos). Von der Benutzung der OverDrive Media Console raten wir Ihnen ab. Erfahrungsgemäß treten hier gehäuft Probleme mit dem Adobe DRM auf.
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine Adobe-ID sowie eine kostenlose App.
Geräteliste und zusätzliche Hinweise

Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.

Mehr entdecken
aus dem Bereich

von Stefan J. Lang; Gerhard K. Lang

eBook Download (2024)
Thieme (Verlag)
59,99